Form 4: Mira Pharmaceuticals CEO Receives Incentive Stock Options
SEC Form 4
Erez Aminov, CEO of Mira Pharmaceuticals, was granted 300,000 incentive stock options with an exercise price of $1.15 on March 26, 2024.
Summary
- Erez Aminov, the CEO of Mira Pharmaceuticals, received 300,000 incentive stock options on March 26, 2024.
- The exercise price for these options is $1.15, which is equal to the closing price of Mira Pharmaceuticals' common stock on the grant date.
- These options were granted under the company's 2022 Amended and Restated Omnibus Incentive Plan.
- 150,000 of the options will vest on September 26, 2024, and the remaining 150,000 will vest on March 26, 2025.
- Aminov also holds 50,000 fully vested options from April 28, 2023, with an exercise price of $5.00, 150,000 fully vested options from August 17, 2023, with an exercise price of $6.50, and 50,000 options from August 17, 2023, that will vest on April 28, 2024, with an exercise price of $6.50.
Sentiment
Score: 7
Explanation: The document is neutral to positive. It reflects a standard executive compensation practice, aligning management's interests with shareholders. The vesting schedule provides a long-term incentive.
Positives
- The granting of incentive stock options aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Granting stock options to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The specific terms of the grant, such as the exercise price and vesting schedule, are tailored to the company's specific circumstances and the executive's role.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Pfizer, Johnson & Johnson, and AbbVie also utilize stock options as part of their executive compensation plans.
- The vesting schedules and exercise prices are typically determined based on factors such as the executive's performance, the company's stock price, and industry benchmarks.
Stakeholder Impact
- Shareholders may view the option grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see it as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/28/2023 | 50,000 stock options were issued to the Reporting Person that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each |
| 08/17/2023 | 150,000 stock options were issued to the Reporting Person which vested in full on August 17,2023 at an exercise price of $6.50 each |
| 08/17/2023 | 50,000 stock options were issued to the Reporting Person which will vest in full on April 28. 2024 at an exercise price of $6.50 each. |
| 03/26/2024 | Date of the transaction: Grant of 300,000 incentive stock options with an exercise price of $1.15. |
| 03/26/2024 | Exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock. |
| 09/26/2024 | 150,000 of the granted options will vest. |
| 03/26/2025 | The remaining 150,000 of the granted options will vest. |
| 03/26/2034 | Expiration date of the incentive stock options. |
| 03/27/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.